Central Retinal Vein Occlusion Clinical Trial
Official title:
Spontaneous Retinal Artery Pulses (SPARs) as a Prognostic Determinant of Central Retinal Vein Occlusions (CRVO) in Patients With or Without Intravitreal Aflibercept Injections
Central retinal vein occlusion (CRVO) is the second most common retinal vascular disease after diabetic retinopathy. It induces circulatory slowdown and blood stasis, which can appear as retinal hemorrhages. CRVO has been classically separated into two clinical forms: ischemic CVRO (possibly associated with cotton wool spots) and non-ischemic CRVO, the former being considered the most serious due to neovascular complications. More recently, a new classification has been suggested by Pierru et al. distinguishing two types of CRVO: type A characterized by low acute blood flow and type B with a slower onset. Type A is particularly associated with younger age, the presence of acute paracentral middle maculopathy, concomitant cilioretinal artery occlusion, and/or pulsatile arterial filling. Type B is more likely to occur in elderly patients, usually with high blood pressure, and multiple hemorrhages are frequently found on fundus examination. A retrospective study had shown a slight difference in favor of pulsatile CRVO in terms of the number of intravitreal anti-angiogenic injections required to treat macular edema and visual acuity changes. However, no statistically significant difference was observed. The objective of this study is to prospectively investigate whether spontaneous retinal artery pulses (SPARs) in patients with type A or B CRVO can be considered as a prognostic factor for the evolution of CRVO.
In order to be able to interpret the results on a homogeneous population, given that several molecules have marketing authorization for the management of macular edema following a CRVO, the therapeutic management will be standardized by the use of aflibercept for patients requiring intravitreal injection, aflibercept being the most widely referenced treatment currently used in the participating centers. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01969708 -
Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A | |
Completed |
NCT01231633 -
Comparison of Initial Ozurdex (Dexamethasone Implant) to Avastin (Bevacizumab) for Treatment of Macular Edema Caused by Central Retinal Vein Occlusion (CRVO)
|
N/A | |
Terminated |
NCT00969293 -
Study to Assess the Safety and Tolerability of a Single Administration of FOV2302 (Ecallantide) in Patients With Macular Edema Associated With Central Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03981549 -
Treatment of Central Retinal Vein Occlusion Using Stem Cells Study
|
Phase 1/Phase 2 | |
Completed |
NCT02274259 -
Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen
|
Phase 4 | |
Completed |
NCT01360385 -
Retinal Ischemia in Central Retinal Vein Occlusion, and the Effects of Treatment With Intravitreal Ranibizumab
|
N/A | |
Not yet recruiting |
NCT00383773 -
Retinal Endo Vascular Surgery for Central Retinal Vein Occlusion
|
N/A | |
Completed |
NCT00952614 -
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
|
N/A | |
Recruiting |
NCT04601701 -
Central Retinal Vein Occlusion (CRVO) Treatment With Bevacizumab and Dexamethasone or Bevacizumab Only.
|
N/A | |
Withdrawn |
NCT03417401 -
Surgical Stabilizer Assisted RVC With rtPA for CRVO
|
Phase 1 | |
Completed |
NCT01976312 -
Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO)
|
Phase 3 | |
Completed |
NCT01724554 -
Impact of Intravitreal Aflibercept Injections on Capillary Non-Perfusion
|
Phase 1/Phase 2 | |
Completed |
NCT01471691 -
Intravitreal Ranibizumab 0.5MG, or 1.0mg for RVO With Macular Edema Previously Receiving Bevacizumab
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01011374 -
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
|
Phase 1 | |
Completed |
NCT03223714 -
Conbercept Ophthalmic Injection for Patients of Central Retinal Vein Occlusion
|
Phase 3 | |
Recruiting |
NCT01827722 -
Ozurdex Versus Ranibizumab Versus Combination for Central Retinal Vein Occlusion
|
Phase 4 | |
Completed |
NCT00906685 -
Bevacizumab for Central Retinal Vein Occlusion Study
|
Phase 3 | |
Recruiting |
NCT02405741 -
Hyperbaric Chamber for Central Retinal Vein Occlusion (CRVO) Patients
|
Phase 2 | |
Recruiting |
NCT01348633 -
Retinal Oxygen Saturation, Blood Flow, Vascular Function and High Resolution Morphometric Imaging in the Living Human Eye
|
N/A |